ALPMY News and Press, Astellas Pharma Inc. ADR From 09/24/18

TOKYO and CHERTSEY, England , Sept. 24, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") announced today that The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a posit...

Quick Take Arvinas Holding ( ARVN ) intends to raise $100 million from the sale of its common stock in a U.S. IPO, per an amended registration statement . The company is advancing a pipeline of drug candidates for the treatment of various cancers. ARVN has enviable licensing partnership...

Today's Top Stories: China asks for WTO sanctions on the US, oil prices climb higher, and Renesas buys IDTI. Click play to listen in your browser. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (f...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). China will ask the World Trade Organization to impose sanctions on the U.S. next week for non-compliance related to a...

Urovant Sciences has filed for its initial public offering . More news on: Urovant Sciences, Astellas Pharma, Inc. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more ...

Pfizer (NYSE: PFE ) and partner Astellas Pharma ( OTCPK:ALPMY ) has amended the clinical research protocols for two trials of enzalutamide, accelerating primary completion dates on both. More news on: Pfizer Inc., Astellas Pharma, Inc. ADR, Astellas Pharma, Inc., Healthcare stocks news, ...

NEW YORK and TOKYO , Aug. 22, 2018 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evalu...

Acquisition furthers Astellas' commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma TOKYO and CAMBRIDGE, England , Aug. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa ,Ph.D., "Astel...

The following slide deck was published by Astellas Pharma, Inc. ADR in conjunction with their 2018 Q2 earnings Read more ...

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Array's melanoma combo gets a guideline nod Company: Array Biopharma ( ARRY ) Therapy:...